Induction of apoptosis in renal tubular cells by histone deacetylase inhibitors, a family of anticancer agents

Journal of Pharmacology and Experimental Therapeutics

Volumn 325, Issue 3, 2008, Pages 978-984

  Dong, Guie ^a   Wang, Lysa ^a   Wang, Cong Yi ^a   Yang, Tianxin ^b   Kumar, M Vijay ^c   Dong, Zheng ^a,c  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE; CISPLATIN; CYTOCHROME C; HISTONE DEACETYLASE INHIBITOR; PIFITHRIN ALPHA; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; PROTEIN P53; TRICHOSTATIN A; VORINOSTAT;

ACETYLATION; ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVATION; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; MITOCHONDRION; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN SECRETION; RAT;

ACETYLATION; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE; CYTOCHROMES C; HISTONE DEACETYLASES; HISTONES; HYDROXAMIC ACIDS; KIDNEY TUBULES, PROXIMAL; MITOCHONDRIA; RATS;

EID: 44249089268     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.137398     Document Type: Article

References (29)

1. Arany I, Herbert J, Herbert Z, and Safirstein RL (2008) Restoration of CREB function ameliorates cisplatin cytotoxicity in renal tubular cells. Am J Physiol Renal Physiol 294:F577-F581.
2. Arany I and Safirstein RL (2003) Cisplatin nephrotoxicity. Semin Nephrol 23:460-464.
3. Bhalla KN (2005) Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 23:3971-3993.
4. Bhatt K, Feng L, Pabla N, Liu K, Smith S, and Dong Z (2007) Effects of targeted Bcl-2 expression in mitochondria or endoplasmic reticulum on renal tubular cell apoptosis. Am J Physiol Renal Physiol 294:F499-F507.
5. Blander G and Guarente L (2004) The Sir2 family of protein deacetylases. Annu Rev Biochem 73:417-435.
6. Bolden JE, Peart MJ, and Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769-784.
7. Cummings BS and Schnellmann RG (2002) Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. J Pharmacol Exp Ther 302:8-17.
8. Dong Z and Wang J (2004) Hypoxia selection of death-resistant cells: a role for Bcl-XL. J Biol Chem 279:9215-9221.
9. Dong Z, Wang JZ, Yu F, and Venkatachalam MA (2003) Apoptosis-resistance of hypoxic cells: multiple factors involved and a role for IAP-2. Am J Pathol 163:663-671.
10. Glozak MA and Seto E (2007) Histone deacetylases and cancer. Oncogene 26:5420-5432.
11. Green DR and Kroemer G (2004) The pathophysiology of mitochondrial cell death. Science 305:626-629.
12. Henderson C, Mizzau M, Paroni G, Maestro R, Schneider C, and Brancolini C (2003) Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA). J Biol Chem 278:12579-12589.
13. Hodawadekar SC and Marmorstein R (2007) Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design. Oncogene 26:5528-5540.
14. Jiang M, Pabla N, Murphy RF, Yang T, Yin XM, Degenhardt K, White E, and Dong Z (2007) Nutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax/Bak activation. J Biol Chem 282:2636-2645.
15. Jiang M, Yi X, Hsu S, Wang CY, and Dong Z (2004) Role of p53 in cisplatin-induced tubular cell apoptosis: dependence on p53 transcriptional activity. Am J Physiol Renal Physiol 287:F1140-F1147.
16. Kelly KJ, Plotkin Z, Vulgamott SL, and Dagher PC (2003) P53 mediates the apoptotic response to GTP depletion after renal ischemia-reperfusion: protective role of a p53 inhibitor. J Am Soc Nephrol 14:128-138.
17. Kelly WK, O'Connor OA, Krug LM, Chiao JH, Heaney M, Curley T, MacGregore-Cortelli B, Tong W, Secrist JP, Schwartz L, et al. (2005) Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23:3923-3931.
18. Marks PA and Breslow R (2007) Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25:84-90.
19. Pabla N, Huang S, Mi QS, Daniel R, and Dong Z (2008) ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis. J Biol Chem 283:6572-6583.
20. Parant J, Chavez-Reyes A, Little NA, Yan W, Reinke V, Jochemsen AG, and Lozano G (2001) Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a nonoverlapping pathway with MDM2 to regulate p53. Nat Genet 29: 92-95.
21. Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, Smyth MJ, and Johnstone RW (2001) The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A 98:10833-10838.
22. Saikumar P, Dong Z, Patel Y, Hall K, Hopfer U, Weinberg JM, and Venkatachalam MA (1998) Role of hypoxia-induced Bax translocation and cytochrome c release in reoxygenation injury. Oncogene 17:3401-3415.
23. Shen J, Huang C, Jiang L, Gao F, Wang Z, Zhang Y, Bai J, Zhou H, and Chen Q (2007) Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines. Biochem Pharmacol 73: 1901-1909.
24. Swan SK (1997) Aminoglycoside nephrotoxicity. Semin Nephrol 17:27-33.
25. Van Vleet TR and Schnellmann RG (2003) Toxic nephropathy: environmental chemicals. Semin Nephrol 23:500-508.
26. Vrana JA, Decker RH, Johnson CR, Wang Z, Jarvis WD, Richon VM, Ehinger M, Fisher PB, and Grant S (1999) Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53. Oncogene 18:7016-7025.
27. Wang X (2001) The expanding role of mitochondria in apoptosis. Genes Dev 15:2922-2933.
28. Wei Q, Alam MM, Wang MH, Yu F, and Dong Z (2004) Bid activation in kidney cells following ATP depletion in vitro and ischemia in vivo. Am J Physiol Renal Physiol 286:F803-F809.
29. Xu WS, Parmigiani RB, and Marks PA (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26:5541-5552.